Glucosyltransferase Mutant Converting Rebaudioside D to Rebaudioside M
Summary
USPTO published patent application US20260092262A1 for Shandong Benyue Biological Technology Co., Ltd covering a glucosyltransferase mutant enzyme that catalyzes conversion of Rebaudioside D (RD) to Rebaudioside M (RM). The mutant contains specific amino acid substitutions at positions 84, 88, 126, 196, and 379 and exhibits significantly higher enzyme activity than wild-type variants. The application was filed September 26, 2025.
What changed
The USPTO published a patent application for a novel glucosyltransferase mutant enzyme developed by Shandong Benyue Biological Technology Co., Ltd. The mutant enzyme catalyzes the bioconversion of Rebaudioside D (RD) to Rebaudioside M (RM), a high-intensity sweetener compound. Key mutations include: proline at position 84 to tryptophan, methionine at position 88 to valine, leucine at position 126 to phenylalanine, asparagine at position 196 to histidine, and leucine at position 379 to isoleucine. The application claims improved enzyme activity and higher conversion rates compared to wild-type glucosyltransferase.
Patent applicants and those developing stevia-derived sweeteners should review the claimed amino acid substitutions and enzyme configurations to assess potential freedom-to-operate implications. Competitors working with similar glucosyltransferase enzymes for sweetener production should evaluate whether their existing patents or products may overlap with the disclosed mutations. No immediate compliance action is required as this is a published patent application rather than an issued patent.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GLUCOSYLTRANSFERASE MUTANT CATALYZING REBAUDIOSIDE D TO PRODUCE REBAUDIOSIDE M AND USE THEREOF
Application US20260092262A1 Kind: A1 Apr 02, 2026
Assignee
Shandong Benyue Biological Technology Co., Ltd
Inventors
Shunbin ZHANG, Liang CHEN, Zhen ZHANG, Boqing DING, Jinpeng JIAO
Abstract
A glucosyltransferase mutant catalyzing RD to produce RM and a use thereof are provided. The glucosyltransferase mutant is obtained by subjecting the amino acid sequence shown in SEQ ID NO: 1 to at least one of the following mutations: mutating proline at position 84 to tryptophan; and/or mutating methionine at position 88 to valine; and/or mutating leucine at position 126 to phenylalanine; and/or mutating asparagine at position 196 to histidine; and/or mutating leucine at position 379 to isoleucine. The use of the mutant in preparation of the RM is also provided. The enzyme activity of the mutant is significantly higher than that of the wild type, and the conversion rate for the preparation of the RM is high.
CPC Classifications
C12N 9/1051 C12N 15/70 C12P 19/18 C12P 19/44 C12N 2800/101
Filing Date
2025-09-26
Application No.
19340916
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.